BOSTON, MA — November 18, 2025 — Emulate, Inc. has announced the launch of its next-generation Brain-Chip R1, a cutting-edge Organ-Chip platform designed to transform neurological drug development through advanced in-vitro modeling of human brain physiology. Developed in partnership with FUJIFILM Cellular Dynamics, Inc. (FCDI), the Brain-Chip R1 integrates human induced pluripotent stem cell (iPSC)-derived neurons and glial cells with Emulate’s microfluidic Organ-Chip technology, creating a dynamic, physiologically relevant environment for studying complex neural functions, disease mechanisms, and therapeutic responses. The collaboration enhances the reliability, reproducibility, and scalability of Emulate’s neurology portfolio, positioning the new platform as a critical tool for improving predictability in CNS drug R&D, reducing clinical attrition, and accelerating preclinical decision-making.
Science Significance
Scientifically, the Brain-Chip R1 represents a major advancement in Organ-Chip engineering, incorporating microfluidic flow, 3D cellular organization, and iPSC-derived human neural cells to recreate highly relevant physiological and biochemical brain functions. The platform supports co-culture of neurons, astrocytes, microglia, and endothelial cells, enabling researchers to model neuroinflammatory cascades, synaptic communication, and barrier permeability with a level of fidelity unattainable in static cell culture systems. The Brain-Chip R1 also allows programmable mechanical, biochemical, and electrical stimulation, supporting disease-specific modeling for conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and treatment-resistant epilepsy. The integration of FCDI’s high-quality iPSC-derived cells enhances scientific reproducibility, enabling more consistent mechanistic insights and drug-response profiling.
Regulatory Significance
From a regulatory standpoint, the Brain-Chip R1 aligns with global initiatives to incorporate New Approach Methodologies (NAMs) into drug-development workflows. Regulatory agencies such as the U.S. FDA, EMA, and MHRA have expressed growing support for organ-chip technologies to generate mechanistic evidence, reduce animal use, and improve predictive validity for human safety. The Brain-Chip R1 contributes to regulatory science by enabling more accurate preclinical assessments of neurotoxicity, BBB penetration, immune-brain interactions, and pharmacodynamic responses that influence dosing and early clinical trial design. As NAM acceptance expands, Emulate’s platform may increasingly support regulatory submissions, qualification programs, and next-generation safety frameworks for CNS therapeutics.
Business Significance
Advertisement
Commercially, the Brain-Chip R1 strengthens Emulate’s leadership in the Organ-Chip market and deepens its strategic relevance for pharmaceutical, biotechnology, and CRO partners focused on neuroscience. The neurological drug market continues to experience significant growth driven by rising rates of Alzheimer’s disease, neurodegenerative disorders, psychiatric conditions, and rare neurological syndromes. By offering a more predictive human-specific platform, Emulate enables drug developers to reduce R&D risk, optimize screening pipelines, and accelerate advancement of CNS assets into clinical proof-of-concept studies. The collaboration with FCDI ensures supply-chain stability and expands Emulate’s value proposition by integrating high-grade human cells, opening opportunities for new subscription models, data-as-a-service platforms, and cross-disciplinary innovation partnerships.
Patients’ Significance
For patients living with debilitating neurological diseases, the Brain-Chip R1 holds the potential to dramatically improve the therapeutic development landscape. By enabling earlier and more accurate identification of effective compounds—and earlier elimination of non-viable candidates—the platform supports faster, safer advancement of treatments targeting severe conditions with high unmet need. Improved predictive capability may reduce late-stage clinical trial failures, ultimately leading to more effective and more accessible CNS therapies. Furthermore, the use of human-derived cells ensures that the disease pathways being studied more closely reflect patient biology, improving the likelihood of delivering disease-modifying interventions for disorders that currently lack curative options.
Policy Significance
The launch aligns with global innovation policies promoting non-animal scientific methods, precision-medicine platforms, and advanced preclinical technologies. Governments and regulatory authorities are actively encouraging integration of organ-chip systems, recognizing their potential to modernize safety testing, improve efficiency, and reduce ethical burdens. The Brain-Chip R1 directly supports policy frameworks such as the FDA Modernization Act, EU chemical safety regulations, and public-private initiatives in neurological innovation. As countries expand funding for neuroscience and alternative testing models, Emulate’s technology stands to play a central role in shaping future R&D infrastructure.
Emulate’s introduction of the Brain-Chip R1, developed in partnership with FUJIFILM Cellular Dynamics, marks a pivotal advancement in neurological drug-development technology. With its highly human-relevant modeling capabilities, regulatory alignment, and strong commercial potential, the platform is positioned to redefine early-stage neuroscience R&D and accelerate progress toward transformative treatments for complex brain disorders. As the pharmaceutical industry intensifies its focus on precision neurology, the Brain-Chip R1 stands out as a powerful innovation poised to drive the next generation of CNS therapeutics.
Source: Emulate, Inc. press release
